Key result
Balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension reduced mean pulmonary artery pressure from 43 to 32.5 mmHg and was associated with a 2.1% periprocedural mortality rate.
Why the study?
Current data regarding balloon pulmonary angioplasty for CTEPH are sparse, and results vary according to local center experience.
Does balloon pulmonary angioplasty improve 6-minute walking distance and is it safe in patients with chronic thromboembolic pulmonary hypertension?
Systematic Review (n=725)
Does balloon pulmonary angioplasty improve 6-minute walking distance and is it safe in patients with chronic thromboembolic pulmonary hypertension?
Absolute Event Rate: 32.5% vs 43%
Balloon pulmonary angioplasty is an effective and relatively safe treatment option for patients with inoperable or persistent CTEPH, improving functional capacity with acceptable complication rates.
BACKGROUND: Balloon pulmonary angioplasty (BPA) is a percutaneous treatment option for patients affected by chronic thromboembolic pulmonary hypertension (CTEPH) and either judged inoperable or with persistent symptoms after pulmonary endoarteriectomy. Current data regarding BPA are sparse and results vary according to local center experience. A systematic review of the literature was performed to better understand the effectiveness and safety of BPA in the treatment of CTEPH. METHODS AND RESULTS: ), and improvement of 6-minute walking distance (from 345 to 442 m). Periprocedural mortality occurred in 2.1% of patients (95% CoI 0.8-4.1) while reperfusion and pulmonary vessel injuries occurred in 9.3% (95% CoI 3.1-18.4) and 2.3% (95% CoI 0.9-4.5) of total BPA sessions, respectively. CONCLUSIONS: Our systematic review suggested that BPA for CTEPH patients was an effective and relatively safe treatment option.
No takes yet. Share an insight, caveat, or question.
Zoppellaro et al. (2019) conducted a systematic review in Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (n=725). Balloon pulmonary angioplasty (BPA) vs. Baseline (before BPA) was evaluated on Mean pulmonary artery pressure (mPAP). Balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension reduced mean pulmonary artery pressure from 43 to 32.5 mmHg and was associated with a 2.1% periprocedural mortality rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: